Neuropeptide Y and PACAP Levels Change During Cystic Fibrosis Lung Exacerbations
Serum neuropeptide Y (NPY) and PACAP levels changed significantly during acute pulmonary exacerbations in cystic fibrosis patients, suggesting neuropeptide involvement in CF lung inflammation.
Quick Facts
What This Study Found
NPY and PACAP serum levels changed significantly during CF pulmonary exacerbations and correlated with clinical outcomes, linking neuropeptide signaling to CF lung inflammation.
Key Numbers
20 CF patients, mean age 8.83 years (±4.37). Three neuropeptides measured: substance P, NPY, PACAP. Blood drawn at admission and 2 weeks post-antibiotics.
How They Did This
Measured serum NPY and PACAP levels in CF patients during acute pulmonary exacerbations and after treatment. Correlated neuropeptide levels with clinical outcomes.
Why This Research Matters
CF lung exacerbations are the main cause of disease progression. If neuropeptides contribute to lung inflammation, targeting them could reduce exacerbation severity and slow lung decline.
The Bigger Picture
Neuropeptides are increasingly recognized as modulators of inflammatory responses across many organs. This study extends the connection to CF lung disease, suggesting the neuro-immune axis plays an underappreciated role in this genetic condition.
What This Study Doesn't Tell Us
Small CF patient cohort typical for rare disease studies. Neuropeptide changes may be secondary to inflammation rather than causative. Correlation does not prove therapeutic potential.
Questions This Raises
- ?Could neuropeptide modulation reduce CF exacerbation severity?
- ?Do NPY and PACAP levels predict impending CF exacerbations?
- ?Would NPY/PACAP measurements add to current CF biomarker panels?
Trust & Context
- Key Stat:
- Neuropeptides in CF NPY and PACAP levels shifted during CF lung exacerbations, suggesting neuropeptide involvement in this genetic lung disease
- Evidence Grade:
- Preliminary evidence: observational study in CF patients with neuropeptide-outcome correlations.
- Study Age:
- Published in 2025. Novel connection between neuropeptide biology and CF lung disease.
- Original Title:
- Treatment of cystic fibrosis pulmonary exacerbation and serum levels of neuropeptides.
- Published In:
- Journal of immunoassay & immunochemistry, 46(6), 637-653 (2025)
- Authors:
- Al-Keilani, Maha S, Bdeir, Roba, Almomani, Basima A, Awad, Samah, Hammouri, Hanan, Al Shalakhti, Tala, Dahabreh, Muna M, Ajlony, Mohammad-Jaafar A
- Database ID:
- RPEP-09825
Evidence Hierarchy
Frequently Asked Questions
What do neuropeptides have to do with cystic fibrosis?
This study found NPY and PACAP — nervous system signaling peptides — change during CF lung infections and correlate with how patients respond to treatment. This suggests the nervous system actively participates in CF lung inflammation.
Could this lead to new CF treatments?
Potentially. If neuropeptides contribute to CF lung inflammation, drugs that modify NPY or PACAP signaling could help manage exacerbations alongside standard antibiotics and anti-inflammatories. More research is needed.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09825APA
Al-Keilani, Maha S; Bdeir, Roba; Almomani, Basima A; Awad, Samah; Hammouri, Hanan; Al Shalakhti, Tala; Dahabreh, Muna M; Ajlony, Mohammad-Jaafar A. (2025). Treatment of cystic fibrosis pulmonary exacerbation and serum levels of neuropeptides.. Journal of immunoassay & immunochemistry, 46(6), 637-653. https://doi.org/10.1080/15321819.2025.2580418
MLA
Al-Keilani, Maha S, et al. "Treatment of cystic fibrosis pulmonary exacerbation and serum levels of neuropeptides.." Journal of immunoassay & immunochemistry, 2025. https://doi.org/10.1080/15321819.2025.2580418
RethinkPeptides
RethinkPeptides Research Database. "Treatment of cystic fibrosis pulmonary exacerbation and seru..." RPEP-09825. Retrieved from https://rethinkpeptides.com/research/al-keilani-2025-treatment-of-cystic-fibrosis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.